A Study to Evaluate the Efficacy and Safety of Mavacamten in Chinese Adults With Symptomatic Obstructive HCM
A Phase III, Randomized, Double-blinded, Placebo-controlled Clinical Study With A Long-term Extension to Evaluate the Efficacy and Safety of Mavacamten in Chinese Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy
Sponsor: LianBio LLC
A PHASE3 clinical study on Obstructive Hypertrophic Cardiomyopathy, this trial is completed. The trial is conducted by LianBio LLC and has accumulated 8 data snapshots since 2022. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
8 versions recorded-
Oct 2024 — Present [monthly]
Completed PHASE3
Status: Active Not Recruiting → Completed
-
Sep 2024 — Oct 2024 [monthly]
Active Not Recruiting PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Active Not Recruiting PHASE3
-
Apr 2024 — Jul 2024 [monthly]
Active Not Recruiting PHASE3
-
Jul 2023 — Apr 2024 [monthly]
Active Not Recruiting PHASE3
▶ Show 3 earlier versions
-
Feb 2023 — Jul 2023 [monthly]
Active Not Recruiting PHASE3
Status: Recruiting → Active Not Recruiting
-
Feb 2022 — Feb 2023 [monthly]
Recruiting PHASE3
Status: Not Yet Recruiting → Recruiting
-
Jan 2022 — Feb 2022 [monthly]
Not Yet Recruiting PHASE3
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- LianBio LLC
For direct contact, visit the study record on ClinicalTrials.gov .